Drug Profile
Research programme: anti-adipocyte monoclonal antibodies - BTG/Pilot Pharmaceuticals
Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Lipid metabolism disorders; Obesity
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 31 May 2007 Discontinued - Preclinical for Lipid metabolism disorders in United Kingdom (unspecified route)
- 31 May 2007 Discontinued - Preclinical for Obesity in North America (Injection)